Acquisitions and Divestitures - Actual Financial Results (Detail) (King [Member], USD $) In Millions, unless otherwise specified	5 Months Ended
	Jul. 03, 2011
King [Member]
Business Acquisition [Line Items]
Revenues	$ 581	[1]
Loss from continuing operations attributable to Pfizer Inc. common shareholders	$ (74)	[1],[2]

[1] From January 31, 2011 (the acquisition date) through Pfizer's second-quarter 2011 domestic and international quarter-ends

[2] Includes purchase accounting adjustments related to the fair value adjustments for acquisition-date inventory estimated to have been sold ($119 million pre-tax), amortization of identifiable intangible assets acquired from King ($71 million pre-tax) and restructuring and integration costs ($159 million pre-tax).